Coral Laboratories passes all AGM resolutions; dividend approved
- All six resolutions at Coral Laboratories' 44th AGM passed with requisite majority
- Final dividend on equity shares for FY26 declared and approved by shareholders
- Special resolution on Non-Executive Director remuneration saw 1.52% votes against
- Routine financial and governance matters received over 99.99% support from public shareholders
*this image is generated using AI for illustrative purposes only.
Coral Laboratories concluded its 44th Annual General Meeting on September 29, 2026, with all six proposed resolutions passed by requisite majority. The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), resulted in the adoption of audited financial statements for FY26 and the declaration of a final dividend on equity shares.
The proceedings were chaired by Sushma Kadkade, Director and CFO, who was elected as the Chairperson by the Directors present. A total of 20 members attended the meeting in person or through authorized representatives, satisfying the requisite quorum under Section 103 of the Companies Act, 2013. The meeting commenced at 12:30 pm and concluded at 12:39 pm.
Resolutions passed
Shareholders transacted both ordinary and special business items as outlined in the meeting notice. The following key resolutions were approved:
- Adoption of Audited Financial Statements: Consideration and adoption of standalone financial statements for FY26, along with Directors' and Auditors' Reports.
- Dividend Declaration: Approval of the final dividend on equity shares for FY26.
- Director Re-appointments: Re-appointment of Sushma Kadkade (DIN: 07791735) and Rajendrasinh Rana (DIN: 09306136), both retiring by rotation under section 152(6) of the Companies Act, 2013.
- Auditor Remuneration: Ratification of remuneration payable to M/S Aatish Dhatrik & Associates, Cost Auditor, for FY27.
- Director Remuneration: Approval of remuneration to Sushma Kadkade in her capacity as Non-Executive Director.
Voting results analysis
The voting data reveals a distinct pattern in shareholder sentiment across different agenda items. While routine matters such as financial adoption, dividend declaration, and auditor remuneration received near-unanimous support from public shareholders (over 99.99% in favor), the special resolution regarding the Non-Executive Director's remuneration faced notable dissent.
| Resolution | Type | Votes For (%) | Votes Against (%) | Result |
|---|---|---|---|---|
| Adoption of FY26 Financials | Ordinary | 100.00 | 0.00 | Passed |
| Declaration of Dividend | Ordinary | 100.00 | 0.00 | Passed |
| Re-appointment: Sushma Kadkade | Ordinary | 99.99 | 0.00 | Passed |
| Re-appointment: Rajendrasinh Rana | Ordinary | 99.99 | 0.00 | Passed |
| Ratification: Cost Auditor Remuneration | Ordinary | 100.00 | 0.00 | Passed |
| Approval: NED Remuneration | Special | 98.48 | 1.52 | Passed |
Governance and attendance
The meeting was conducted in compliance with the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant MCA and SEBI circulars. SARK & Associates LLP served as the Scrutinizer for remote e-voting and voting at the AGM. The Audit reports did not contain any qualifications or adverse remarks, and thus were not read out during the session.
Directors present included Girish Dhameja (Whole-time Director), Malay Doshi (Independent Director and Chairperson of Audit Committee), and Pooja Hindia (Independent Director). Representatives from the Statutory Auditor, Internal Auditor, Secretarial Auditor, and the Scrutinizer were also present. Voting results were announced within 48 hours of the meeting's conclusion and disseminated to stock exchanges and the NSDL website.
Historical Stock Returns for Coral Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.17% | -4.85% | -11.53% | +53.56% | +16.32% | +42.55% |
How will the 1.52% dissent on Non-Executive Director remuneration influence future governance reforms or shareholder engagement strategies at Coral Laboratories?
What specific growth initiatives or capital expenditure plans are outlined in the adopted FY26 financial statements that could impact the company's medium-term valuation?
How does the declared final dividend yield compare to industry peers, and what does this signal about management's confidence in future cash flow stability?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
